Palliative radiation 2Gy x 2Fx in indolent B-cell non-Hodgkin lymphoma stage 3-4
Keywords:
lymphoma, 2 Gray for 2 fractionsAbstract
Indolent B-cell non-Hodgkin lymphoma is highly responsive to chemotherapy and radiotherapy. However, many patients experience multiple relapse, especially in stage III-IV. Therefore, 10-year and 15-year overall survival are very low. In case of high tumor burden but not suitable for chemotherapy, palliative low-dose radiotherapy using 2 Gray for 2 fractions produces promising results (complete response 61% and partial response 27%). Side effects of radiotherapy are sparse. Sophisticated radiotherapy techniques are unnecessary due to low-dose radiation. This radiotherapy schedule is convenient for patients and technicians, especially in the limited-resource institutions. Furthermore, the schedule prolongs time to local progression for about 2 years.
References
Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol. 2017;10:405-415.
Longo DL. The REAL Classification of lymphoid neoplasms: one clinician’s view. In: Rosenberg S, editors. PPO Updates. Philadelphia: Lippincott, 1995. P. 1–12.
Grogan TM, Miller TP, Fisher RI. A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification. Hematol Oncol Clin North Am. 1997;11:819-46.
Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575-84.
Bunworasate U, Siritanaratanakul N, Khuhapinant A, Lekhakula A, Rujirojindakul P, Sirijerachai C, et al. A Nationwide Prospective Multicenter Study of Clinical Features and Outcomes of Non-Hodgkin Lymphoma in Thailand: An Analysis of 939 Cases. Blood (ASH Annual Meeting Abstracts). 2011;118:2064.
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555-62.
Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30:3848-53.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424-35.
Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;1:1110-7.
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-23.
Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506-13.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-10.
Cohen JJ, Duke RC, Chervenak R, Sellins KS, Olson LK. DNA fragmentation in targets of CTL: An example of programmed cell death in the immune system. Adv Exp Med Biol 1985;184:493–508.
Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1987;139:3199-206.
Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood. 2007;110:1116-22.
Ganem G, Lambin P, Socié G, Girinsky T, Bosq J, Pico JL, et al. Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematol Oncol. 1994;12:1-8.
Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol. 1997;42:49-51.
Girinsky T, Guillot-Vals D, Koscielny S, Cosset JM, Ganem G, Carde P, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148-55.
Jóhannsson J, Specht L, Mejer J, Jensen BA. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys. 2002;54:1466-70.
Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474-80.
Ng M, Wirth A, Ryan G, MacManus M, Davis S. Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin's lymphoma. Australas Radiol. 2006;50:222-7.
Luthy SK, Ng AK, Silver B, Degnan KO, Fisher DC, Freedman AS, et al. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol. 2008;19:2043-7.
Chan EK, Fung S, Gospodarowicz M, Hodgson D, Wells W, Sun A, et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;81:e781-6.
Russo AL, Chen YH, Martin NE, Vinjamoori A, Luthy SK, Freedman A, et al. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 2013;86:121-7.
Saleh K, Michot JM, Schernberg A, Lazarovici J, Chahine C, Danu A, et al. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. Cancer Med. 2020. doi: 10.1002/cam4.2796. [Epub ahead of print]
Imber BS, Chau K, Goldberg E, Joffe E, Yahalom J. Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. Leuk Lymphoma. Epub 2020 Feb 9:1-4. doi: 10.1080/10428194.2020.1716222.
Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86:930-5.
König L, Stade R, Rieber J, Debus J, Herfarth K2. Radiotherapy of indolent orbital lymphomas: Two radiation concepts. Strahlenther Onkol. 2016;192:414-21.
Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39:1095-1100.
Girinsky T, Paumier A, Ferme C, Hanna C, Ribrag V, Leroy-Ladurie F, et al. Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients. Int J Radiat Oncol Biol Phys. 2012;83:e385-9.
Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15:457-63.
Downloads
How to Cite
Issue
Section
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
